2020 wins top of the froths for biotech stocks
It's official: dramatic share price jumps in response to clinical data have become more common.
2020 drug approvals rise despite Covid-19
Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.
Focus on Covid-19 does not distract the FDA
Non-Covid-19 medical device approvals tick up alongside the agency’s pandemic efforts.
The pandemic releases its grip on clinical trials
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.
Astounding success greets newly public device makers
2020 was a bountiful year for medtechs making their public debut, with one group, Inari Medical, more than quadrupling in value.
Medtechs rake in the venture cash
In terms of private investments, 2020 was the year of the liquid biopsy.
After a big year, biotech flotations have much to do
Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.
Medtech deal-making stands firm in difficult times
It takes more than a pandemic to stop medical device companies merging.
